[{"orgOrder":0,"company":"Sernova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Thyroid Cell","moa":"T3\/4","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Sernova","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sernova \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sernova \/ Inapplicable"},{"orgOrder":0,"company":"Marea Therapeutics","sponsor":"ProBioGen","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Partnership","leadProduct":"MAR002","moa":"GHR","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Marea Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marea Therapeutics \/ ProBioGen","highestDevelopmentStatusID":"5","companyTruncated":"Marea Therapeutics \/ ProBioGen"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-KHK","moa":"Ketohexokinase","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRV-101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VX-264","moa":"Undisclosed","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : PRV-101

                          Therapeutic Area : Endocrinology

                          Study Phase : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Publication results demonstrates that a preclinical prototype of Provention's polyvalent coxsackievirus B (CVB) vaccine, PRV-101, is well-tolerated, immunogenic and highly protective in relevant animal models.

                          Product Name : PRV-101

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 18, 2020

                          Lead Product(s) : PRV-101

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The parternship aims to deliver clinical material for MAR002, Marea’s investigational anti-growth hormone receptor (GHR) antibody for the treatment of acromegaly.

                          Product Name : MAR002

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 05, 2025

                          Lead Product(s) : MAR002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : ProBioGen

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details :

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 03, 2025

                          Lead Product(s) : Thyroid Cell

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : SAB-142 is a human alternative to rabbit anti-thymocyte globulin, SAB-142’s mechanism of action is analogous to that of rabbit ATG, which is being clinically validated in the clinical trials for T1D.

                          Product Name : SAB-142

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 21, 2024

                          Lead Product(s) : SAB-142

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.

                          Product Name : SAB-142

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 19, 2023

                          Lead Product(s) : SAB-142

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.

                          Product Name : SAB-142

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 01, 2023

                          Lead Product(s) : SAB-142

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : VX-264 is an investigational cell therapy in which allogeneic human stem cell-derived islets are encapsulated in a channel array device designed to shield the cells from the body’s immune system. It is currently being evaluated for patients with T1D.

                          Product Name : VX-264

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 03, 2023

                          Lead Product(s) : VX-264

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypogl...

                          Product Name : MBX 1416

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 08, 2023

                          Lead Product(s) : MBX 1416

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes. The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial.

                          Product Name : BMF-219

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 10, 2023

                          Lead Product(s) : BMF-219

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : SAB will use the funds to clinically advance SAB-142, a fully-human alternative to rabbit anti-thymocyte globulin (rATG), its lead therapeutic candidate for type 1 diabetes (T1D).

                          Product Name : SAB-142

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          February 10, 2023

                          Lead Product(s) : SAB-142

                          Therapeutic Area : Endocrinology

                          Highest Development Status : IND Enabling

                          Sponsor : RA Capital Management

                          Deal Size : $130.0 million

                          Deal Type : Private Placement

                          blank